Core Microbiota in Central Lung Cancer With Streptococcal Enrichment as a Possible Diagnostic Marker

Bello, Salvador; Vengoechea, Jose Javier; Ponce-Alonso, Manuel; Figueredo, Ana L.; Mincholé, Elisa; Rezusta, Antonio; Gambó, Paula; Pastor, Juan Manuel; Galeano, Javier; Campo, R. del

doi:10.1016/j.arbr.2020.05.017

Cited by 14 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, M. restricta was identified as a marker species in LC group that showed significant difference from all the other five groups. In accordance with our results, Malassezia was significantly enriched in bronchial biopsy samples from patients with central lung cancer compared with HCs ( Bello et al, 2021 ). Few is known about the relations of fungal species and the LC development, however, the roles of Malassezia spp.…”

Section: Discussionsupporting

confidence: 92%

“…When compared to these limited data, our study validated some of the previous results but also provided some inconsistent conclusions. For instance, a lung microbiota analysis of patients with central lung cancer showed a higher abundance of Candida in healthy controls and enrichment of Malassezia in patients, which is consistent with our results ( Bello et al, 2021 ). In an analysis of BALF in idiopathic pulmonary fibrosis (IPF) patients, the mycobiome showed no significant difference in the overall mycobiome composition between the IPF group and control group, and both groups were dominated by Candida species ( Fabbrizzi et al, 2021 ).…”

Section: Discussionsupporting

confidence: 92%

“…Recently, Malassezia has been recognized as an emerging infectious pathogen ( Delhaes et al, 2012 ). This genus has been shown to be associated with several chronic inflammatory diseases, including AS, CF pulmonary exacerbation (CFPE) and inflammatory bowel disease (IBD) ( van Woerden et al, 2013 ; Sokol et al, 2017 ; Soret et al, 2020 ; Bello et al, 2021 ). In our study, Malassezia was identified as the most abundant genus in all five disease groups and was much less abundant in the HC group.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Upper respiratory tract mycobiome alterations in different kinds of pulmonary disease

Ding

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

IntroductionThe human respiratory tract is considered to be a polymicrobial niche, and an imbalance in the microorganism composition is normally associated with several respiratory diseases. In addition to the well-studied bacteriome, the existence of fungal species in the respiratory tract has drawn increasing attention and has been suggested to have a significant clinical impact. However, the understanding of the respiratory fungal microbiota (mycobiome) in pulmonary diseases is still insufficient.MethodsIn this study, we investigated the fungal community composition of oropharynx swab (OS) samples from patients with five kinds of pulmonary disease, including interstitial lung disease (ILD), bacterial pneumonia (BP), fungal pneumonia (FP), asthma (AS) and lung cancer (LC), and compared them with healthy controls (HCs), based on high-throughput sequencing of the amplified fungal internal transcribed spacer (ITS) region.ResultsThe results showed significant differences in fungal composition and abundance between disease groups and HCs. Malassezia was the most significant genus, which was much more abundant in pulmonary diseases than in the control. In addition, many common taxa were shared among different disease groups, but differences in taxa abundance and specific species in distinct disease groups were also observed. Based on linear discriminant analysis effect size (LefSe), each group had its characteristic species. Furthermore, some species showed a significant correlation with the patient clinical characteristics.DiscussionOur study deepened our understanding of the respiratory tract mycobiome in some diseases that are less studied and identified the commonalities and differences among different kinds of pulmonary disease. These results would provide the solid basis for further investigation of the association between the mycobiome and pathogenicity of pulmonary diseases.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Upper respiratory tract mycobiome alterations in different kinds of pulmonary disease

Ding

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…In this study, ROC analysis showed that the AUC of Streptococcus in BALF was 0.680, which had limited predictive ability for lung cancer, similar to the AUC value of 0.693 observed by Liu et al (2018) in PSB samples. In contrast, Bello et al (2021) observed an AUC of 0.897 for Streptococcus in bronchial biopsies from 25 Spanish patients with central lung cancer and 16 controls. It is worth mentioning that when we combined the three genera Streptococcus, Prevotella, and Arthrobacter with the most significant proportions at the genus level, the AUC was 0.877, which has good predictive power, indicating that the combination of genera can better predict lung cancer to a certain extent.…”

Section: Discussionmentioning

confidence: 82%

Streptococcus pneumoniae promotes migration and invasion of A549 cells in vitro by activating mTORC2/AKT through up-regulation of DDIT4 expression

et al. 2022

View full text Add to dashboard Cite

IntroductionDysbiosis of the lower airway flora is associated with lung cancer, of which the relationship between Streptococcus, especially pathogenic Streptococcus pneumoniae (S. pneumoniae), and the progression of lung cancer are unclear.MethodsBronchoalveolar lavage fluid (BALF) samples were prospectively collected from patients with pulmonary nodules during diagnostic bronchoscopy, and finally included 70 patients diagnosed with primary lung cancer and 20 patients with benign pulmonary nodules as the disease control group. The differential flora was screened by 16S ribosomal RNA (rRNA) gene amplicon sequencing. An in vitro infection model of lung adenocarcinoma (LUAD) cells exposed to S.pneumoniae was established to observe its effects on cell migration and invasion ability. Exploring the molecular mechanisms downstream of DDIT4 through its loss- and gain-of-function experiments.Results16S rRNA sequencing analysis showed that the abundance of Streptococcus in the lower airway flora of lung cancer patients was significantly increased. After exposure to S. pneumoniae, A549 and H1299 cells significantly enhanced their cell migration and invasion ability. The results of DDIT4 loss- and gain-of-function experiments in A549 cells suggest that up-regulation of DDIT4 activates the mTORC2/Akt signaling pathway, thereby enhancing the migration and invasion of A549 cells while not affecting mTORC1. Immunofluorescence (IF) and fluorescence in situ hybridization (FISH) showed that S. pneumoniae was enriched in LUAD tissues, and DDIT4 expression was significantly higher in cancer tissues than in non-cancerous tissues. The increased expression of DDIT4 was also related to the poor prognosis of patients with LUAD.DiscussionThe data provided by this study show that S. pneumoniae enriched in the lower airway of patients with lung cancer can up-regulate DDIT4 expression and subsequently activate the mTORC2/AKT signal pathway, thereby increasing the migration and invasion abilities of A549 cells. Our study provides a potential new mechanism for targeted therapy of LUAD.

show abstract

“…If the intestinal microbiota increases the effect of NAD boosting drugs, their concomitant use with antimicrobial agents should be prescribed only in patients where the presence of neoplastic disease can be ruled out. Bacteria are frequently associated with tumors ( Xu et al, 2020 ; Dumont-Leblond et al, 2021 ); for instance, the bronchial environments of lung tumors bronchial is enriched in Streptococcus harboring PncA nicotine amidase ( Bello et al, 2021 ). The activity of this bacterial protein might protect neoplastic tissues from NAD-targeting anti-cancer drugs by supplying nicotinic acid to the tumor cells, feeding the deamidated biosynthesis pathway to fulfill their high demand for NAD.…”

Section: Discussion Microbiota Modulation and Drugs Acting On Nad Met...mentioning

confidence: 99%

Interventions in Nicotinamide Adenine Dinucleotide Metabolism, the Intestinal Microbiota and Microcin Peptide Antimicrobials

Baquero

Campo

Martínez

2022

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

A proper NADH/NAD + balance allows for the flow of metabolic and catabolic activities determining cellular growth. In Escherichia coli, more than 80 NAD + dependent enzymes are involved in all major metabolic pathways, including the post-transcriptional build-up of thiazole and oxazole rings from small linear peptides, which is a critical step for the antibiotic activity of some microcins. In recent years, NAD metabolism boosting drugs have been explored, mostly precursors of NAD + synthesis in human cells, with beneficial effects on the aging process and in preventing oncological and neurological diseases. These compounds also enhance NAD + metabolism in the human microbiota, which contributes to these beneficial effects. On the other hand, inhibition of NAD + metabolism has been proposed as a therapeutic approach to reduce the growth and propagation of tumor cells and mitigating inflammatory bowel diseases; in this case, the activity of the microbiota might mitigate therapeutic efficacy. Antibiotics, which reduce the effect of microbiota, should synergize with NAD + metabolism inhibitors, but these drugs might increase the proportion of antibiotic persistent populations. Conversely, antibiotics might have a stronger killing effect on bacteria with active NAD + production and reduce the cooperation of NAD + producing bacteria with tumoral cells. The use of NADH/NAD + modulators should take into consideration the use of antibiotics and the population structure of the microbiota.

show abstract

Core Microbiota in Central Lung Cancer With Streptococcal Enrichment as a Possible Diagnostic Marker

Cited by 14 publications

References 33 publications

Upper respiratory tract mycobiome alterations in different kinds of pulmonary disease

Upper respiratory tract mycobiome alterations in different kinds of pulmonary disease

Streptococcus pneumoniae promotes migration and invasion of A549 cells in vitro by activating mTORC2/AKT through up-regulation of DDIT4 expression

Interventions in Nicotinamide Adenine Dinucleotide Metabolism, the Intestinal Microbiota and Microcin Peptide Antimicrobials

Contact Info

Product

Resources

About